Erschienen in:
16.01.2020 | Original Contributions
Combined antisclerostin antibody and parathyroid hormone (1–34) synergistically enhance the healing of bone defects in ovariectomized rats
verfasst von:
Jinti Lin, M.D., Jun Wu, M.D., Shuaibo Sun, M.D., Kai Chen, M.D., Hongqiang Wu, Renjin Lin, M.D., Chengwei Zhou, M.D., Jianzhong Kong, M.D., Kailiang Zhou, M.D., Xiaolong Shui, M.D.
Erschienen in:
Zeitschrift für Gerontologie und Geriatrie
|
Ausgabe 2/2020
Einloggen, um Zugang zu erhalten
Abstract
Osteoporotic bones heal more slowly and ineffectively than normal bones. A combination of antibodies against sclerosing protein (Scl-Ab), and parathyroid hormone 1–34 (PTH 1–34) may improve healing. A standard osteoporotic rat model was established 12 weeks after bilateral ovarian resection (OVX). Bone defects were created in the right femora of 80 rats, which were randomly divided into 4 groups: control, Scl-Ab (25 mg/kg twice weekly), PTH (60 μg/kg of PTH 1–34 three times a week) and PTH plus Scl-Ab. After 12 weeks of treatment the rats were sacrificed and blood and the distal femora were harvested for biochemical evaluation, histology, microcomputed tomography and biomechanical testing. Compared to the control group, monotherapy and combination therapy with PTH and/or Scl-Ab promoted the formation of new bone, enhanced maximum femoral loading and increased the levels of procollagen type I N‑terminal propeptide (PINP) and osteocalcin. The administration of PTH + Scl-Ab maximally enhanced bone defect healing. Combination treatment was better than either treatment alone, indicating a synergistic effect.